PMID- 32500979
OWN - NLM
STAT- MEDLINE
DCOM- 20210309
LR  - 20210309
IS  - 0033-2100 (Print)
IS  - 0033-2100 (Linking)
VI  - 74
IP  - 1
DP  - 2020
TI  - [i]Clostridioides difficile[/i] infection in patients with end stage renal 
      disease. Is it preventable?
PG  - 11-21
LID - 10.32394/pe.74.02 [doi]
AB  - [i]Clostridioides difficile[/i] infection (CDI) is a leading cause of a 
      healthcare-associated diarrhea worldwide. Recently, an increased number of new 
      cases and growing mortality due to CDI have been observed. Patients suffering 
      from end-stage renal disease (ESRD) are most exposed to CDI. It has been proven 
      that CDI in patients receiving renal replacement therapy (RRT) significantly 
      increases mortality, prolongs hospitalization and increases the cost of 
      treatment. Important risk factors of CDI in ERSD patients include hospitalization 
      or stay in an intensive care unit in the last 90 days, HIV infection, bacteremia, 
      prolonged antibiotic therapy and hypoalbuminemia. Cirrhosis, age over 65 years, 
      hypoalbuminemia, longer hospitalization time and use of antibiotics are 
      significant risk factors of death. Effective methods of preventing CDI include 
      hand hygiene with soap and water, isolation of infected patients in a private 
      room with a dedicated toilet, the use of masks, gloves, disinfection of the 
      environment and systematic education and control of medical personnel, as well as 
      rational antibiotic policy. In addition, it is important to avoid antibiotics 
      with a proven risk of CDI, caution use of proton pump inhibitors (PPI) and H2 
      receptor antagonists. It is also important in the prevention of CDI in people 
      with ERSD, to apply a fast diagnostic since the onset of the first symptoms. The 
      use of probiotics and bile acids in the primary prevention of CDI requires 
      further research. It seems that knowledge of these factors and methods of 
      prevention will significantly reduce morbidity and mortality due to CDI.
CI  - (c) National Institute of Public Health - National Institute of Hygiene.
FAU - Lis, Lukasz
AU  - Lis L
AD  - Research and Development Center, Provincial Specialist Hospital in Wroclaw, 
      Poland.
FAU - Konieczny, Andrzej
AU  - Konieczny A
AD  - Wroclaw Medical University, Department of Nephrology and Transplantation 
      Medicine.
FAU - Zlobicka, Kinga
AU  - Zlobicka K
AD  - Research and Development Center, Provincial Specialist Hospital in Wroclaw, 
      Poland.
FAU - Witkiewicz, Wojciech
AU  - Witkiewicz W
AD  - Research and Development Center, Provincial Specialist Hospital in Wroclaw, 
      Poland.
FAU - Hruby, Zbigniew
AU  - Hruby Z
AD  - Research and Development Center, Provincial Specialist Hospital in Wroclaw, 
      Poland.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Przegl Epidemiol
JT  - Przeglad epidemiologiczny
JID - 0413725
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Clostridioides difficile
MH  - Clostridium Infections/complications/*prevention & control
MH  - Hand Hygiene
MH  - Humans
MH  - Intensive Care Units
MH  - Kidney Failure, Chronic/*microbiology
MH  - Poland
OTO - NOTNLM
OT  - clostridioides difficile
OT  - end-stage renal disease
OT  - pseudomembranous enterocolitis
EDAT- 2020/06/06 06:00
MHDA- 2021/03/10 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/03/10 06:00 [medline]
AID - 10.32394/pe.74.02 [doi]
PST - ppublish
SO  - Przegl Epidemiol. 2020;74(1):11-21. doi: 10.32394/pe.74.02.